Background {#Sec1}
==========

The Coagulase-negative Staphylococci (CoNS) are normal flora which often cause infection associated with implanted appliances and devices, especially in the old, very young children and immune-compromised patients \[[@CR1], [@CR2]\]. On human body, there is a widespread distribution of CoNS from normal flora to those that cause severe diseases \[[@CR3], [@CR4]\]. Acquisition of genes result in the conversion of commensal staphylococci into invasive pathogens \[[@CR5]\]. The vast majority of infections caused by CoNS results in hospitalization \[[@CR6]\] and they are among the five most commonly reported pathogens in nosocomial infections \[[@CR7]\]. Many of the CoNS species are commonly resistant to antimicrobials used currently against staphylococcal infections \[[@CR8], [@CR9]\]. The spread of multi-drug resistant CoNS strains has been promoted by the use of antibiotics in hospitals which has provided a reservoir of antimicrobial resistant strains. The genetic exchange between CoNS and *Staphylococcus aureus (S. aureus)* and the widespread prevalence of methicillin resistance among CoNS species is a great public health concern \[[@CR5], [@CR9], [@CR10]\].

The rising trend of antimicrobial resistant staphylococci species including CoNS \[[@CR11]--[@CR15]\] worldwide requires national antimicrobial resistance prevention policy and updated treatment guidelines which are based on national antimicrobial resistance surveillance. However, developing countries like Ethiopia have financial constraints to conduct national antimicrobial resistance survey. Small scale studies funded by various organizations are conducted and these studies could provide ample evidence to fulfill the gap in national antimicrobial surveillance data if they are summarized and synthesized to draw national estimate of national antimicrobial resistance prevalence. To this end, we had previously conducted a meta-analysis of resistance of *S. aureus* to antimicrobial agents in Ethiopia \[[@CR16]\]. The finding of the study revealed a very high level of *S. aureus* resistance to almost to all of antimicrobial agents commonly used in Ethiopia. Similarly, CoNS are important opportunistic pathogens showing a growing threat of antimicrobial resistance and becoming a difficult-to- treat pathogens. There is a need to have summarized evidence on AMR burden among CoNS to draw national estimate of CoNS antimicrobial resistance prevalence. The current study focuses on CoNS species while the previous study entirely focuses on *S. aureus* \[[@CR16]\]*.* The two studies are separate and there is no overlapping data. However the two studies followed similar study design and objectives.

To the best of our knowledge, there is neither nationwide prevalence surveillance and resistance data nor meta-analysis or systematic review on prevalence of antimicrobial resistance of CoNS in Ethiopia. However, many small scale studies are conducted in many parts of the country. The studies had clear differences in setting, population, methodology, findings, and other characteristics. The purpose of this study was, therefore, to determine prevalence and antimicrobial resistance of CoNS using the best available literature from Ethiopia.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

Meta-analysis of prevalence and antimicrobial resistance of CoNS was conducted using the best available evidence from Ethiopia.

Literature search strategy {#Sec4}
--------------------------

To identify potentially eligible studies, databases of Pub Med, Google Scholar, Hinari, Scopus and directory of open Access Journals (DOAJ) were searched until December 2016. Two of the authors (SS and SF) independently searched for relevant studies to be included. Selection of the study was done by the two authors independently. Consensus was reached on discussion with the third author (SD) whenever disagreement arose. Endnote software was used to manage the references. Articles indexed in Pub Med were directly downloaded using Endnote while those not found in Pub Med are manually added to Endnote. The reference lists of the identified studies were manually searched to identify additional relevant studies for inclusion.

The search was done using various key words combined by Boolean search conjunctions 'AND', 'OR' and 'NOT'. These combined key words are, 'Staphylococci' AND 'antimicrobial resistance AND Ethiopia', 'Staphylococci' AND 'antimicrobial susceptibility' AND 'Ethiopia', 'Staphylococci' AND 'antibiotic resistance' AND 'Ethiopia', 'Staphylococci' AND 'antibiotic susceptibility' AND 'Ethiopia', 'Staphylococci' AND 'drug resistance' AND 'Ethiopia', 'Staphylococci' AND 'drug susceptibility' AND 'Ethiopia', "Staphylococci' AND 'antibacterial resistance' AND 'Ethiopia', 'Staphylococci' And 'antibacterial susceptibility' AND 'Ethiopia'.

### Study selection procedures and criteria {#Sec5}

Two-stage selection of the articles was conducted independently by two of the authors (SS and SF). In the first stage, the titles and abstracts of all retrieved articles were reviewed and grouped as eligible when they address the study question, otherwise dropped from further review. In the second stage, eligible articles were reviewed in full detail for decision on inclusion.

### Eligibility criteria {#Sec6}

Articles were selected based on predefined inclusion criteria. Included articles in this study were those that had the following characteristics: Prospective or retrospective studies, original journal articles, with antimicrobial susceptibility test data according to the criteria of the Clinical Laboratory Standards Institute (CLSI) \[[@CR17]\], studies which defined antimicrobial resistance range according to CLSI manual, and those that used only clinical isolates. Duplicate studies, studies with small number of isolates (1--9), studies conducted other than clinical subjects like on foods, food handlers' belongings, health workers' belongings, health workers' carriage or animals and of non-infectious carriage were excluded.

### Data extraction {#Sec7}

Excel spreadsheets prepared by SD were used for data extraction. The characteristics of studies extracted included first author name, year of publication, place of study, study design, total number of CoNS, number of resistant CoNS isolates, and isolation source. The primary outcome of this study was prevalence and antimicrobial resistant CoNS. If the proportion of sensitive isolates (x) was reported, the number of resistant isolates was calculated by multiplying the number of total isolates (y) by one minus the proportion of sensitive isolates (1-x). The proportion of CoNS is obtained from the division of CoNS positive population by total population under the study.

### Risk of bias assessment {#Sec8}

The methodological quality of each included study was assessed using the quality assessment checklist for prevalence studies as used in the study \[[@CR18]\]. Graphs of the summary of the risk of bias were developed using RevMan 5.3 (Cochrane Informatics and Knowledge Management Department, London, UK).

### Statistical analysis {#Sec9}

Statistical analyses were conducted using Stata version 13.0 (Statacorp, LP, college station, TX). The prevalence values were pooled using the *metaprop* command in Stata \[[@CR19]\]. Heterogeneity of the studies was assessed using the I^2^ statistic. Because of significant heterogeneity amongst the studies, the random-effects model (REM) was used to estimate the pooled proportion and 95% CIs using the DerSimonian and Laird method \[[@CR20]\]. The Freeman-Turkey double arcsine transformation was used to avoid the missing of proportions near or at 0 and 1 from meta-analysis \[[@CR21]\]. Subgroup analysis was done by study design, isolation source and study area. The presence of publication bias was tested using Egger's test \[[@CR22]\]. This meta-analysis was conducted as per the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines \[[@CR23]\].

Results {#Sec10}
=======

Included studies and characteristics {#Sec11}
------------------------------------

Pub Med database search yielded 591, and Google database yielded 5920. After removal of the duplications, 5329 articles remained for further examination. Title and abstract screening reduced the number of eligible articles to 42 for full text evaluation. Twenty-one articles \[[@CR13]--[@CR15], [@CR24]--[@CR41]\] satisfied the criteria for inclusion for meta-analysis and twenty-one studies were excluded with reasons. Five studies did not address the study question (proportion of resistant CoNS) and were excluded \[[@CR42]--[@CR46]\]. The other sixteen studies with small number of isolates (less than 10) \[[@CR47]--[@CR59]\] were also excluded (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow diagram of retrieval of studies: Number of studies screened, assessed for eligibility, and included in the meta-analysis with reasons

Among total of 8047 patients who tested for CoNS, 647 were positives and the isolates were from ear discharge, eye discharge, blood, wound infection, surgical site infection, mixed samples and urine sample. Eleven studies were primary data \[[@CR13], [@CR15], [@CR25], [@CR27], [@CR28], [@CR30], [@CR36]--[@CR40]\] while nine studies were secondary data (records from hospitals or regional laboratories) \[[@CR14], [@CR24], [@CR26], [@CR29], [@CR31]--[@CR35]\]. The characteristics of included studies were summarized in Table [1](#Tab1){ref-type="table"}. Identification of CoNS was conducted using culture on blood agar, Gram-staining, catalase/coagulase test, and cocktail of biochemical assays for carbohydrate fermentation or utilization of specific substrate in all included studies. Kirby Bauer disk diffusion method was used for determination of antimicrobial susceptibility test.Table 1Characteristics of the studies included in the meta-analysesNoStudyStudy periodStudy areaIsolate sourceData typeSample size[No]{.ul} of CoNS positive samples1.Hailu et al. 2016 \[[@CR24]\]2013--2015BahirdarEar dischargeSecondary368342.Abera et al. 2008 \[[@CR25]\]2006BahirdarSSI, wound, ear and eye discharges and throat swabsPrimary221593.Biadglegn et al. 2009 \[[@CR26]\]2003--2008BahirdarUrineSecondary529104.Mama et al. 2014 \[[@CR15]\]2013JimmaWoundPrimary145215.Shiferaw et al. 2015 \[[@CR13]\]2014DessieEye dischargesPrimary160516.Sewunet et al. 2013 \[[@CR36]\]2010Adiss AbabaWoundPrimary50157.Guta et al. 2014 \[[@CR27]\]2010--2011HawassaSSIPrimary100268.Mengesha et al. 2014 \[[@CR28]\]2012MekeleSSIPrimary128189.Kibret and Abera 2010 \[[@CR34]\]2003--2010Dessieurine, ear discharge, eye discharge and wound swabSecondary31493310.Kibret and Abera 2014 \[[@CR35]\]2003--2010DessieUrineSecondary14041711.Tenssay 2002 \[[@CR38]\]1997--1998JimmaPus, blood, urine, and stool samplesPrimary5458912.Wasihun et al. 2015 \[[@CR41]\]2014--2015MekeleEar dischargeSecondary5144413.Lema et al. 2012 \[[@CR39]\]2006--2007Addis AbabaWoundPrimary2456814.Dagnew et al. 2013 \[[@CR29]\]2006--2012GondarBloodSecondary3903015.Godebo et al. 2013 \[[@CR30]\]2011JimmaWoundPrimary3221416.Muluye et al. 2013 \[[@CR31]\]2009--2012GondarEar dischargeSecondary2282317.Muluye et al. 2014 \[[@CR14]\]2009--2012GondarEye dischargesSecondary1021718.Tesfaye et al. 2013 \[[@CR40]\]2012-O2012JimmaEye dischargesPrimary1981519.Tadesse et al. 2014 \[[@CR37]\]2012HawassaUrinePrimary2441920.Aweke et al. 2014 \[[@CR33]\]2012--2013HawassaEye dischargesSecondary2812621.Washun and Zemen 2015 \[[@CR41]\]2014--2015MekeleEar dischargesPrimary16217

Publication bias, heterogeneity and risk of bias assessment {#Sec12}
-----------------------------------------------------------

High heterogeneity, I^2^ ranging from 67.65 to 96.76%; *p*-values ≤0.01 was observed. Eggers' test didn't detect publication bias. Overall, most of the prospective studies demonstrated a low risk of bias; however that of retrospective relatively a higher risk of bias. The methodological quality of the studies included is illustrated in (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Summary of risk of bias for all the included studies

Prevalence of coagulase-negative staphylococci {#Sec13}
----------------------------------------------

The pooled prevalence of CoNS clinical isolates from Ethiopia was 12%(95% CI: 8, 16%), I2 = 96.88%. Subgroup analysis by study design showed significantly higher prevalence of CoNS in prospective studies compared to retrospective studies (16%(95% CI: 11, 21%) versus 6%(95% CI: 3, 10%)) (Fig. [3](#Fig3){ref-type="fig"}). Higher prevalence from surgical site infection (SSI) (19%) was observed compared to urinary tract infection (3%) (Fig. [4](#Fig4){ref-type="fig"}). A subgroup analysis by study region showed a higher value of CoNS in Addis Ababa 28%, significantly higher than Mekelle, Jimma, Dessie, and Gondar (Fig. [5](#Fig5){ref-type="fig"}).Fig. 3Forest plot of prevalence of CoNS from Ethiopia by study designFig. 4Forest plot of prevalence of CoNS from Ethiopia by isolation sourceFig. 5Forest plot of prevalence of CoNS from Ethiopia by area (region)

Prevalence of antimicrobials resistant coagulase-negative staphylococci {#Sec14}
-----------------------------------------------------------------------

High level of resistance by CoNS was observed to most commonly used antimicrobials from Ethiopia and the resistance level was summarized in Table [2](#Tab2){ref-type="table"}. Methicilin resistance was 37% (95 %CI: 21, 55%), Additional file [1](#MOESM1){ref-type="media"}: Figure S1; to vancomycin 11% (95% CI: 0, 35%), Additional file [2](#MOESM2){ref-type="media"}: Figure S2; to penicillin 58%(95% CI: 42, 74%), Additional file [3](#MOESM3){ref-type="media"}: Figure S3; to amoxicillin 42% (95% CI: 23, 61%), Additional file [4](#MOESM4){ref-type="media"}: Figure S4; to amoxicillin-clavulanate 27%(95% CI: 2, 27%), Additional file [5](#MOESM5){ref-type="media"}: Figure S5; to ampicillin 64%(95% CI: 46, 80%), Additional file [6](#MOESM6){ref-type="media"}: Figure S6. Similarly, resistance to other antimicrobials was high; to tetracycline 60% (95% CI: 49, 70%), Additional file [7](#MOESM7){ref-type="media"}: Figure S7; to doxycycline 36% (95% CI:19,55, 81.18%, Additional file [8](#MOESM8){ref-type="media"}: Figure S8; to sulfametaxazole-trimethoprim 50% \[95% CI: 36, 64%), Additional file [9](#MOESM9){ref-type="media"}: Figure S9; to ceftriaxone (27% \[95% CI: 18, 38%\]), Additional file [10](#MOESM10){ref-type="media"}: Figure S10; to cephalothin (32% \[95% CI: 7, 62%\], Additional file [11](#MOESM11){ref-type="media"}: Figure S11; to norfloxacin (39% \[95% CI: 24, 56%\], Additional file [12](#MOESM12){ref-type="media"}: Figure S12; to chloramphenicol (40% \[95% CI: 23, 58%\], Additional file [13](#MOESM13){ref-type="media"}: Figure S13; to clindamycin (11% \[95% CI: 2, 27%\]) Additional file [14](#MOESM14){ref-type="media"}: Figure S14; and to ciprofloxacin (14% \[95% CI: 6, 22%\]), Additional file [15](#MOESM15){ref-type="media"}: Figure S15; to gentamicin 27% (95%, CI:19, 36%), Additional file [16](#MOESM16){ref-type="media"}: Figure S16; and to erythromycin 30% (95%, CI:20, 42%) Additional file [17](#MOESM17){ref-type="media"}: Figure S17. Forest plots of the abovementioned antimicrobials resistance were placed as additional file respectively from methicilin to erythromycin (Additional file [1](#MOESM1){ref-type="media"}: Figure S1, Additional file [2](#MOESM2){ref-type="media"}: Figure S2, Additional file [3](#MOESM3){ref-type="media"}: Figure S3, Additional file [4](#MOESM4){ref-type="media"}: Figure S4, Additional file [5](#MOESM5){ref-type="media"}: Figure S5, Additional file [6](#MOESM6){ref-type="media"}: Figure S6, Additional file [7](#MOESM7){ref-type="media"}: Figure S7, Additional file [8](#MOESM8){ref-type="media"}: Figure S8, Additional file [9](#MOESM9){ref-type="media"}: Figure S9, Additional file [10](#MOESM10){ref-type="media"}: Figure S10, Additional file [11](#MOESM11){ref-type="media"}: Figure S11, Additional file [12](#MOESM12){ref-type="media"}: Figure S12, Additional file [13](#MOESM13){ref-type="media"}: Figure S13, Additional file [14](#MOESM14){ref-type="media"}: Figure S14, Additional file [15](#MOESM15){ref-type="media"}: Figure S15, Additional file [16](#MOESM16){ref-type="media"}: Figure S16 and Additional file [17](#MOESM17){ref-type="media"}: Figure S17) and the proportions were summarized in Table [2](#Tab2){ref-type="table"}.Table 2Prevalence of CoNS resistance to different antimicrobial agents in EthiopiaAntimicrobial AgentFrost plot presented inNo. of studiesNo. of isolate testedNo. of resistant isolatePooled AMR Proportion (95% CI)I^2^ (*p*-value)1.MethicilinS193171400.37 (0.21,0.55)88.70 (*P* ≤ 0.01)2.VancomycinS27169240.11 (0.00,0.35)92.54 (*P* ≤ 0.01)3.PenicillinS3143892250.57 (0.40,0.73)89.60 (*P* ≤ 0.01)4.AmoxicillinS49198810.42 (0.23,0.61)84.37 (P ≤ 0.01)5.Amoxicillin-clavulanateS55120330.27 (0.02,0.65)93.77 (*P* ≤ 0.01)6.AmpicillinS6133382160.64 (0.46,0.80)89.92 (*P* ≤ 0.01)7.TetracyclineS7153882390.60 (0.49,0.70)76.30(*P* ≤ 0.01)8.DoxycyclineS86162630.36 (0.19,0.55)81.18(*P* ≤ 0.01)9.Sulfametaxazole-trimethoprimS9164132070.50 (0.36,0.64)86.95(*P* ≤ 0.01)10.CeftriaxoneS1014317950.27 (0.18,0.38)71.91 (*P* ≤ 0.01)11.CephalothinS11561230.32 (0.07,0.62)78.01 (*P* ≤ 0.01)12.NorfloxacinS128177580.39 (0.24,0.56)74.57 (*P* ≤ 0.01)13.ChloramphenicolS13123111410.40 (0.23,0.58)88.94(*P* ≤ 0.01)14.ClindamycinS145209390.11 (0.02,0.27)85.72 (*P* ≤ 0.01)15.CiprofloxacinS1513316510.14 (0.06,0.22)73.49 (*P* ≤ 0.01)16.GentamicinS16174311230.27 (0.19,0.36)69.04 (*P* ≤ 0.01)17.ErythromycinS17164131380.30 (0.20,0.42)81.12 (*P* ≤ 0.01)

Comparisons of the prevalence of CoNS resistance to different antimicrobial agents were outlined in (Fig. [6](#Fig6){ref-type="fig"}). The magnitude of CoNS resistance to the different antimicrobials ranges from 11% to vancomycin and clindamycin to 64% to ampicillin.Fig. 6Comparison of prevalence of CoNS resistance to different antimicrobials from Ethiopia

Discussion {#Sec15}
==========

In this meta-analysis, we estimated the pooled prevalence and antimicrobial resistance of CoNS to 17 different antimicrobials commonly used in Ethiopia. Twenty-one studies were included in this meta-analysis and the number of studies included in each meta-analysis varies from 5 to 17. Overall, the 21 studies provided evidence concerning the prevalence and antimicrobial resistance of CoNS to different antimicrobials based on isolates identified from 8047 patients. The study revealed that CoNS resistances to commonly available antimicrobials were high, ranging from 11% (vancomycin) to 64% (clindamycin and amipicilin) in Ethiopia.

The emergence of antimicrobial resistant staphylococcus species is a global concern. Our previous studies showed that MRSA is unexpectedly high (97.0%) in Hawassa University comprehensive specialized hospital, Ethiopia \[[@CR12]\] and meta-analysis on MRSA in Ethiopia demonstrated very high level of resistance (47% \[95% CI: 33, 61%\]) \[[@CR16]\] and in other meta-analysis similar results were observed (32.5% \[95% CI, 24.1 to 40.9%\]) \[[@CR60]\]. The current findings on MRCoNS showed similarly high resistance (34 95% CI \[17, 53%\]). These findings signified that methicillin resistance is increasing and becoming of public health concern in Ethiopia. The prevalence of MRCoNS was relatively lower than MRSA. This may be due to infrequent occurrence of infection with CoNS compared to *S. aureus* resulting in decreased antimicrobial exposure. However, CoNS is continuously evolving from commensal staphylococci into invasive pathogens and then to resistant strains and possibly gaining resistant genes from *S. aureus* \[[@CR5]\].

There is no published meta-analysis focusing on antimicrobial resistance of CoNS for comparison, however the pooled prevalence of CoNS resistance in this study showed a higher level of resistance compared to other studies in different parts of the world \[[@CR8], [@CR61]\]. A higher prevalence of resistance was observed in a study conducted in India compared to the current study \[[@CR62], [@CR63]\]. A higher rate of resistance in this study may be due to a higher exposure, irrational use of antimicrobial agents and lack of infection prevention policies, especially in hospital settings.

Subgroup analysis by study design showed a higher pooled prevalence of CoNS in prospective studies (17%) compared to retrospective studies (6%). This could be attributed to missing data and poorly defined denominator in the case of retrospective design. A higher prevalence of CoNS in SSI may be due to the fact that CoNS are opportunistic pathogens causing infections in patients with implanted medical devices and surgical procedures \[[@CR8], [@CR64]\]. A higher prevalence of CoNS in Addis Ababa compared to other regions can be explained by lager exposure rate in Tikur Anbessa referral hospital where referral cases with severe diseases of recurrent infection treated from all over the country.

Aminoglycosides and fluoroquinolones showed relatively lower level of resistance in this study. A lower level of resistance observed could suggest the development of mutant resistant strains for commonly used first line agents made the microbes easily susceptible to less commonly used antimicrobials \[[@CR65], [@CR66]\]. The lower rate of resistance observed with clindamycin may be due to its infrequent use in Ethiopia resulting in lower exposure rate.

The cause of antimicrobial resistance is multifactorial, from lack of infection prevention to irrational use of antimicrobials by health professionals and patients \[[@CR67]\]. It is a common practice that antimicrobials can be obtained over-the-counter in Ethiopia. This mishandling of antimicrobials is the main cause of emergence of resistance \[[@CR68]\]. Absence of culture techniques and routine antimicrobial susceptibility testing and consequent empiric therapy is a reason for selection of resistant strains and spread. Therefore, in line to strategies for prevention and containment of resistance there is a need for innovative ways of halting resistance. Combination therapy and search for novel antimicrobials will provide a vital role to counter this global problem.

Significant risk of bias was observed with five retrospective studies. This risk of bias was due to unclear denominator in retrospective study during data retrieval and possibly loss of samples during retrieval resulting in non-response. In addition, all of the included studies were conducted in small particular localities and non-representative convenient samplings technique was used. Therefore, the limitations of this study arise from the characteristics of included studies. First, this is in vitro antimicrobial resistance testing and direct inference to clinical outcome calls for caution. Secondly, many studies were conducted in limited localities and mainly in teaching hospitals in bigger cities where patients with advanced and severe stages of diseases with recurrent infection are treated. For this reason, the resistance prevalence could have been overrated. Lastly, studies were not conducted on phenotypic characteristics of resistance, lacking details of molecular characteristic of resistant strains.

Conclusions {#Sec16}
===========

This meta-analysis revealed that CoNS has gotten resistant to many of common antibiotics used in Ethiopia. Launching national antimicrobial treatment and use policy guideline is essential for fighting the antimicrobial resistance. Further research focusing on factors promoting antimicrobial resistance, molecular genetics and outcome studies are warranted. Antimicrobial susceptibility should be determined prior to treatment of infections.
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:   Methicillin resistant *Staphylococcus aureus*
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